Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi

Lancet

Volumn 348, Issue 9019, 1996, Pages 17-24

  Fine, Paul E M ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; INACTIVATED VACCINE; LEPROSY VACCINE;

ADOLESCENT; ADULT; ARTICLE; BCG VACCINATION; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; INCIDENCE; INTRADERMAL DRUG ADMINISTRATION; LEPROSY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALAWI; MALE; MYCOBACTERIUM LEPRAE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TUBERCULOSIS;

EID: 0030572468     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)02166-6     Document Type: Article

References (31)

1. Murray CJL, Lopez AD, eds. Global comparative assessments in the health sector: disease burden, expenditures and intervention strategies. Geneva: WHO, 1994.
2. Bloom BR, Fine PEM. The BCG experience: implications for future vaccines against tuberculosis. In: Bloom BR, ed. Tuberculosis: pathogenesis, protection and control. Washington, DC: American Society of Microbiology, 1994: 531-57.
3. Fine PEM. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995; 346: 1339-45.
4. WHO Expanded programme on immunization: immunization schedules in the European region, 1995. WHO Wkly Epidemiol Rec 1995; 70: 221-27.
5. WHO. Global tuberculosis programme and global programme on vaccines. Statement on BCG revaccination for the prevention of tuberculosis. WHO Wkly Epidemiol Rec 1995; 70: 229-31.
6. Sepulveda RL, Parcha C, Sorenson RU. Case-control study of the efficacy of BCG immunization against pulmonary tuberculosis in young adults in Santiago, Chile. Tuber Lung Dis 1993; 73: 372-77.
7. Convit J, Samson C, Zuniga M, et al. Immunoprophylactic trial with combined Mycobacterium leprae/BCG vaccine against leprosy: preliminary results. Lancet 1992; 339: 446-50.
8. Fine PEM, Pönnighaus JM. Background, design and prospects of the Karonga Prevention Trial, a leprosy vaccine trial in Northern Malawi. Trans R Soc Trop Med Hyg 1988; 82: 810-17.
9. Pönnighaus JM, Fine PEM, Gruer PJK, et al. The Karonga Prevention Trial: a leprosy and tuberculosis vaccine trial in Northern Malawi: I. Methods of the vaccination phase. Lepr Rev 1993; 64: 338-56.
10. Pönnighaus JM, Fine PEM, Sterne JAC, et al. Efficacy of BCG against leprosy and tuberculosis in Northern Malawi. Lancet 1992; 339: 636-39.
11. Pönnighaus JM, Fine PEM, Sterne JACet al. incidence rates of leprosy in Karonga District, Northern Malawi: patterns by age, sex, BCG status and classification. Int F Lepr. 61:1994;10-23.
12. Sterne JAC, Pönnighaus JM, Fine PEM, Malema S. Geographic determinants of leprosy in Karonga District, Northern Malawi. Int F Epidemiol 1995; 24: 1211-22.
13. Fine PEM, Job CK, McDougall AC, Meyers WM, Pönnighaus JM. Comparability between histopathologists in the diagnosis and classification of leprosy. Int F Lepr Other Mycobact Dis 1986; 54: 614-25.
14. Pönnighaus JM, Fine PEM, Bliss L. Certainty levels in the diagnosis of leprosy. Int F Lepr Other Mycobact Dis 1987; 55: 454-62.
15. Pönnighaus JM, Mwanjasi LJ, Fine PEM, et al. Is HIV infection a risk factor for leprosy? Int F Lepr Other Mycobact Dis 1991; 59: 221-28.
16. Sterne JAC, Turner AC, Fine PEM, et al. Testing for antibody to human immunodeficiency virus type 1 in a population in which mycobacterial diseases are endemic. F Infect Dis 1995; 172: 543-46.
17. Pönnighaus JM, Fine PEM, Moreno C Hypersensitivity to dextran in BCG vaccine. Lancet. 337:1991;1039.
18. Rodrigues LC, Diwan VK, Wheeler JG. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int F Epidemiol 1993; 22: 1154-58.
19. Lwin K, Sundaresan T, Gyi MM, et al. BCG vaccination of children against leprosy: fourteen-year findings of the trial in Burma. Bull World Health Organ 1985; 63: 1069-78.
20. Bagshawe A, Scott GC, Russell DA, Wigley SC, Merianos A, Berry G. BCG vaccination in leprosy: final results of the trial in Karimui, Papua New Guinea. Bull World Health Organ 1989; 67: 389-99.
21. Stanley SJ, Howland C, Stone MM, Sutherland I. BCG vaccination of children against leprosy in Uganda: final results. F Hyg (Camb) 1981; 87: 235-48.
22. Tripathy SP The case for BCG. Ann N Y Acad Med Sci. 19:1983;11-21.
23. Springett VH, Sutherland I. Re-examination of the variations in the efficacy of BCG against tuberculosis in clinical trials. Tuber Lung Dis 1994; 75: 227-33.
24. Wade HW. BCG-induced activations. Int F Lepr 1960; 28: 179-81.
25. Breslow NE, Day NE. Statistical methods in cancer research: II. The design and analysis of cohort studies. Lyon: International Agency for Research on Cancer, 1987.
26. Boerrigter G, Pönnighaus JM. Does the introduction of WHO-MDT influence trends in the incidence of leprosy? - the Malawian experience. Lepr Rev 1993; 64: 227-35.
27. Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, Ellner J. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am F Respir Crit Care Med 1995; 151: 129-35.
28. Wallis RS, Vjecha M, Amir-Tahmasseb Met al. Influence of tuberculosis on human immunodeficiency virus (HIV-1): enhanced cytokine expression and elevated B2-microglobulin in HIV-1 associated tuberculosis. F Infect Dis. 167:1993;43-48.
29. Weltman AC, Rose DN. The safety of Bacille Calmette-Guérin vaccination in HIV infection and AIDS. AIDS 1993; 7: 149-57.
30. Tuberculosis Prevention Trial Madras Trial of BCG vaccines in South India for tuberculosis prevention. Indian F Med Res. 72((suppl)):1980;1-74.
31. Fine PEM Reflections on the elimination of leprosy. Int F Lepr Other Mycobact Dis. 60:1992;71-80.